Biocon Ltd. News and Updates

Keep track of all breaking news on Biocon Ltd. from all sources in a single place.

Load latest

Biocon Ltd.

07 Aug 2025

422.50

0.37%

Biocon Q1 results: Net profit down 95%, revenue rises 15% to 4,022 cr

Business Standard

Biocon's Q1 net profit declines sharply due to high base from one-time gain last year; biosimilars, CRDMO and generics drive revenue and operational growth

Biocon Ltd. has gained 24.48% in the last 6 Months

Biocon Q1 Results: Profit Slumps 95% Even As Revenue Rises

NDTV Profit | 07 Aug 2025

Biocon Ltd.

16 Jul 2025, 10:13AM

422.50

0.37%

Biocon shares jump 3% after USFDA approval for diabetes insulin drug

Business Standard

At 09:30 AM, Biocon shares were trading at 398.15, up by 1.97 per cent on the National Stock Exchange.

Biocon Ltd. has gained 24.48% in the last 6 Months

Biocon Ltd.

03 Jul 2025

422.50

0.37%

Karnataka CM's remark on Covid vaccines 'factually incorrect': Biocon chief

Business Standard

Biocon founder Kiran Mazumdar-Shaw on Thursday opposed Karnataka Chief Minister Siddaramaiah's remarks linking covid-19 vaccines with a spate of heart attack deaths in the state's Hassan district, saying such claims are "'factually incorrect" and "misleading". Siddaramaiah has suggested that the recent heart attack deaths in Hassan district may be linked to the vaccination drive. He had also claimed the vaccines were 'hastily' approved. In a social media post, Shaw said "covid-19 vaccines developed in India were approved under the Emergency Use Authorisation framework, following rigorous protocols aligned with global standards for safety and efficacy. To suggest that these vaccines were 'hastily' approved is factually incorrect and contributes to public misinformation." "These vaccines have saved millions of lives and, like all vaccines, may cause side effects in a very small number of individuals. It is important to acknowledge the science and data-driven processes behind their...

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

02 Jul 2025

422.50

0.37%

Biocon climbs 3% on plans to file approvals for generic weight-loss drug

Business Standard

Biocon share price gained 2.5 per cent after reports suggested that the company is planning to file for generic versions of Novo Nordisk A/S's Ozempic and Wegovy

Biocon Ltd. has gained 18.63% in the last 1 Month

Biocon aims to lead copycat Wegovy sales in Canada from next year

Business Line | 02 Jul 2025 1 more

Biocon Ltd.

27 Jun 2025

422.50

0.37%

Biocon drops plan to launch weight-loss drugs in China, executive says

Business Line

There is ample capacity and players available in China, says Amit Kaptain, head of Biocon's commercial active pharmaceutical ingredients business

Biocon Ltd. has gained 25.82% in the last 1 Year

Biocon Ltd.

24 Jun 2025

422.50

0.37%

Biocon's 4,500 crore equity raise to reduce debt by FY26, says SP

Business Standard

S&P says Biocon will bring down adjusted debt to Rs 20,000 crore by FY26 through equity issuance, with strong cash flows aiding deleveraging and future capex needs